Daily Cardiology Research Analysis
Analyzed 158 papers and selected 3 impactful papers.
Summary
Three impactful cardiology studies stand out today: a multicenter randomized trial shows oral nicorandil significantly reduces contrast-associated acute kidney injury in high-risk PCI with a dose-response effect; an individual patient-level meta-analysis finds early SGLT2 inhibitor initiation in acute heart failure increases diuresis and reduces 60-day death/rehospitalization; and mechanistic work identifies carbon dioxide as a triple vasodilator with a new NIRS-CO2 readout that tracks microvascular disease.
Research Themes
- Renal protection strategies during high-risk PCI
- Early decongestion and outcomes in acute heart failure
- Microvascular physiology and noninvasive vascular reactivity assessment
Selected Articles
1. Nicorandil to Prevent Contrast-Associated Kidney Injury in High-Risk PCI.
In a multicenter RCT of 585 PCI patients with renal dysfunction, oral nicorandil significantly reduced contrast-associated AKI versus hydration alone, with a dose-response favoring 10 mg TID over 5 mg TID. Findings support nicorandil as an accessible, peri-procedural renoprotective strategy.
Impact: Demonstrates a simple, low-cost, dose-dependent intervention that reduces CA-AKI in a common high-risk PCI population, with immediate practice implications.
Clinical Implications: Consider peri-procedural oral nicorandil (10 mg TID) as an adjunct to hydration for PCI patients with renal dysfunction to lower CA-AKI risk; integrate into cath lab protocols while awaiting long-term outcome data.
Key Findings
- Randomized 585 high-risk PCI patients to high-dose nicorandil, conventional-dose, or hydration-only control.
- CA-AKI incidence was 19.8% in control vs 10.9% (conventional) and 8.7% (high-dose), indicating a dose-response benefit.
- Secondary biomarker assessments (creatinine, BUN, cystatin C, CRP) were prespecified; primary endpoint reduction drove overall benefit.
Methodological Strengths
- Prospective multicenter randomized controlled design with dose stratification
- Clinically hard primary endpoint (CA-AKI) with clear event-rate separation
Limitations
- Blinding status and adjudication details not reported in abstract
- Long-term renal and cardiovascular outcomes not assessed
Future Directions: Confirm findings in diverse health systems, assess long-term renal and clinical outcomes, and compare nicorandil with other nephroprotective strategies.
BACKGROUND: Patients with renal dysfunction remain at high risk for contrast-associated acute kidney injury despite standard peri-procedural volume administration. This study aims to investigate whether peri-procedural oral nicorandil provides additional protection in this population, and to evaluate its potential dose-response relationship. METHODS: We conducted a prospective, multicenter, randomized controlled trial enrolling patients with percutaneous coronary intervention with renal dysfunction. Participants were randomized into 3 groups, including a high-dose nicorandil group (30 mg/d, 10 mg 3× daily), a conventional-dose nicorandil group (15 mg/d, 5 mg 3× daily), and a saline hydration-only control group. The primary end point was the incidence of contrast-associated acute kidney injury. Secondary end points included changes in serum creatinine, blood urea nitrogen, CysC (cystatin C), and CRP (C-reactive protein). RESULTS: A total of 585 patients were recruited and randomized. The incidence of contrast-associated acute kidney injury was significantly lower in both nicorandil groups, with 19.8% (39/197) in the control group, compared with 10.9% (21/193) in the conventional-dose group and 8.7% (17/195) in the high-dose group ( CONCLUSIONS: Adjunctive nicorandil, particularly at a dose of 10 mg 3× daily, significantly reduced the incidence of contrast-associated acute kidney injury in percutaneous coronary intervention patients with renal dysfunction. Oral nicorandil represents a readily available, effective, and dose-dependent prophylactic strategy to enhance renoprotection. Future studies are warranted to evaluate the long-term clinical benefits of this intervention. REGISTRATION: URL: https://www.chictr.org.cn; Unique identifier: CTR2200064264.
2. Carbon dioxide is a triple vasodilator.
CO2 elicits vasodilation via three coordinated mechanisms—endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels—and responses are blunted in vascular disease. A novel NIRS-CO2 time-to-intersection metric captured disease-associated delays in microvascular reactivity, supporting translational diagnostic utility.
Impact: Provides a unifying mechanistic framework for CO2 vasodilation and introduces a feasible noninvasive biomarker (NIRS-CO2) for microvascular health with potential applications in PAD/CAD.
Clinical Implications: NIRS-CO2 may evolve into a bedside tool to assess integrated endothelial and myogenic microvascular function; CO2-evoked pathways (NO-sGC, K+ channels, carbonic anhydrases) suggest therapeutic targets and rationale for CA inhibitor use.
Key Findings
- CO2 acts via endothelial NO/sGC, EDHF (SKCa/IKCa), and myogenic K+ channels, functioning as a triple vasodilator.
- CO2-evoked vasodilator responses are delayed and blunted in diseased human and murine arteries.
- A NIRS-CO2 time-to-intersection (TTI) metric correlates with PAD/CAD status and detects risk-associated vascular delay phenotypes.
- Carbonic anhydrase activity couples tissue metabolism to the duration and extent of CO2 vasodilation.
Methodological Strengths
- Multi-system validation including knockout mice, pharmacologic dissection, and human cohort readouts
- Development and benchmarking of a novel physiological biomarker (NIRS-CO2) against FMD
Limitations
- Human cohort size and case mix not fully detailed; exploratory analyses require confirmation
- Diagnostic thresholds and clinical workflows for NIRS-CO2 remain to be standardized
Future Directions: Validate NIRS-CO2 across diverse vasculopathies, define diagnostic thresholds, and test interventional modulation of NO-sGC and K+ channel pathways including CA inhibitors.
AIMS: Carbon dioxide (CO2) can regulate blood flow and is applied therapeutically in intensive care units to treat brain injury, as well as in balneotherapy for peripheral arterial disease (PAD) and diabetic angiopathy; however, its mode of action remains unclear. METHODS AND RESULTS: The vasoactive CO2 effects were tested in arteries of healthy C57BL/6J mice, hypertensive apolipoprotein E-deficient mice, and soluble guanylyl cyclase (sGC) knockout mice in a small vessel myograph with and without pharmacologically intervening in endothelium- and/or vascular smooth muscle-mediated vasodilation. CO2-based Near Infrared Spectroscopy (NIRS-CO2) was developed to assess vasoreactivity of the skin microcirculation to CO2 in healthy individuals, PAD and coronary artery disease (CAD) patients, and was compared with flow-mediated dilation (FMD). We identified CO2 as a triple vasodilator mimicking the actions of endothelium-derived relaxing factor (nitric oxide, NO), endothelium-derived hyperpolarization factor (EDHF), and direct myogenic vasodilators. CO2 engaged endothelial NO/sGC, endothelial small-/intermediate-conductance calcium-activated potassium channels (SKCa/IKCa), and myogenic voltage-gated (KV) and IKCa potassium channels, respectively, acting as a triple vasodilator. CO2-evoked vasodilator responses were blunted and delayed in diseased human and murine arteries. In the human cohort, the NIRS-CO2-derived time-to-intersection (TTI) of the HbO2 and HHb curves, capturing the delay phenotype, showed a strong association with PAD/CAD status and, in exploratory analyses, also distinguished young individuals with cardiovascular risk factors, supporting NIRS-CO2 as a physiological readout that integrates endothelial and myogenic components of microvascular reactivity. Duration and extent of CO2 vasodilation were coupled to tissue metabolism through vascular carbonic anhydrases (CAs), providing a mechanism for vasculometabolic coupling and one for clinically approved CA inhibitors. CONCLUSION: NIRS-CO2 provides a feasible readout of CO2-evoked microvascular responsiveness and shows disease-associated alterations in our PAD/CAD cohort. Larger studies will validate generalizability across vasculopathies and clarify the relative contributions of NO-sGC versus K+ channel-linked mechanisms for future therapeutic translation.
3. Early effects of SGLT2 inhibitors in acute heart failure: an individual patient-level meta-analysis.
Pooling IPD from six RCTs (n=623), early SGLT2 inhibitor therapy in acute HF increased 24-hour diuresis (median 3500 vs 2700 mL), with effects persisting to Day 5, without raising natriuresis. It also reduced the 60-day composite of death and HF rehospitalization (adjusted HR 0.62).
Impact: Supports early initiation of SGLT2 inhibitors during acute HF admission to enhance decongestion and improve short-term outcomes, refining timing of therapy beyond chronic HF indications.
Clinical Implications: Initiate SGLT2 inhibitors early during hospitalization for acute HF to augment diuresis without increasing natriuresis and to lower 60-day adverse outcomes; integrate with loop diuretics and guideline-directed therapy.
Key Findings
- Early SGLT2i increased 24-hour diuresis (median 3500 vs 2700 mL; P<0.001) and the effect persisted through Day 5.
- No increase in natriuresis despite greater diuresis, suggesting aquaretic or hemodynamic mechanisms.
- Reduced 60-day composite of all-cause mortality and HF rehospitalization (adjusted HR 0.62) and favorable win ratio (1.45).
- No safety signal differences across subgroups.
Methodological Strengths
- Individual patient-level meta-analysis of randomized trials with consistent endpoints
- Assessment of both physiological (diuresis, natriuresis) and clinical outcomes with adjusted analyses
Limitations
- Total sample size is modest across six trials; heterogeneity in trial protocols possible
- Longer-term outcomes beyond 60 days not evaluated
Future Directions: Larger pragmatic RCTs to confirm early-initiation strategies, mechanistic studies to disentangle aquaretic vs hemodynamic effects, and integration with diuretic dosing algorithms.
BACKGROUND AND AIMS: Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are effective in the treatment of chronic heart failure (HF) and stabilized acute HF. Early clinical effects on decongestion in patients with acute HF remain uncertain. We aimed to evaluate the effect of early SGLT2i treatment on diuresis, in-hospital and post-discharge outcomes in patients with acute HF. METHODS: Individual patient-level data were pooled from randomized controlled trials comparing SGLT2i with placebo/control in patients with acute HF, in which information on diuretic response as a measure of decongestive response was available. The main outcome was 24-h diuresis. Secondary outcomes included diuresis up to Day 5, natriuresis, all-cause mortality, and HF rehospitalization at 30 and 60 days, and a win ratio analysis combining death, HF rehospitalization, and 24-h diuresis. RESULTS: Overall, 623 patients from 6 trials were included. Median age was 67 years, and 38% were female. Compared with placebo/control, patients randomized to SGLT2i showed higher 24-h diuresis 3500 (2038-4650) vs 2700 (1950-3625) ml (P < .001). This effect of SGLT2i on diuresis persisted through Day 5. SGLT2i therapy did not increase natriuresis at any timepoint. The 60-day risk of the composite outcome of all-cause mortality and HF rehospitalization was lower with SGLT2i (adjusted hazard ratio 0.62 (95% CI 0.41-0.95), P-value = .028). The win ratio of the hierarchical endpoint favoured SGLT2i (win ratio: 1.45 (95% CI: 1.16-1.82), P-value = .001). Safety outcomes and subgroup analyses did not differ between groups. CONCLUSION: SGLT2i therapy, initiated early in admission for acute HF, increased diuresis and reduced the risk of post-discharge mortality and HF readmission.